Novartis Deal to Evaluate Accelr8's BACcel Platform Expires Without Further Extension | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A technology evaluation agreement between Accelr8 Technology and Novartis has expired without further extension by Novartis, Accler8 said today.

As a result, Accelr8 will be able to negotiate with other firms for its BACcel system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.